10. Role of high dimensional technology in preeclampsia (omics in preeclampsia).

Metabolomics Proteomics epigenomics genomics microbiomics omics preeclampsia transcriptomics

Journal

Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582

Informations de publication

Date de publication:
18 Nov 2023
Historique:
received: 01 06 2023
revised: 05 07 2023
accepted: 06 08 2023
medline: 24 11 2023
pubmed: 24 11 2023
entrez: 23 11 2023
Statut: aheadofprint

Résumé

Preeclampsia is a pregnancy-specific disease that has no known precise cause. Integrative biology approach based on multi-omics has been applied to identify upstream pathways and better understand the pathophysiology of preeclampsia. At DNA level, genomics and epigenomics studies have revealed numerous genetic variants associated with preeclampsia, including those involved in regulating blood pressure and immune response. Transcriptomics analyses have revealed altered expression of genes in preeclampsia, particularly those related to inflammation and angiogenesis. At protein level, proteomics studies have identified potential biomarkers for preeclampsia diagnosis and prediction in addition to revealing the main pathophysiological pathways involved in this disease. At metabolite level, metabolomics has highlighted altered lipid and amino acid metabolisms in preeclampsia. Finally, microbiomics studies have identified dysbiosis in the gut and vaginal microbiota in pregnant women with preeclampsia. Overall, omics technologies have improved our understanding of the complex molecular mechanisms underlying preeclampsia. However, further research is warranted to fully integrate and translate these omics findings into clinical practice.

Identifiants

pubmed: 37995432
pii: S1521-6934(23)00134-7
doi: 10.1016/j.bpobgyn.2023.102427
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102427

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to declare.

Auteurs

Lina Youssef (L)

BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, IDIBAPS, University of Barcelona, Barcelona, Spain; Institut de Recerca August Pi Sunyer (IDIBAPS), Barcelona, Spain; Josep Carreras Leukaemia Research Institute, Hospital Clinic/University of Barcelona Campus, Barcelona, Spain. Electronic address: lyoussef@recerca.clinic.cat.

Lea Testa (L)

BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, IDIBAPS, University of Barcelona, Barcelona, Spain.

Francesca Crovetto (F)

BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, IDIBAPS, University of Barcelona, Barcelona, Spain; Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, Spain.

Fatima Crispi (F)

BCNatal | Barcelona Center for Maternal Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Déu, IDIBAPS, University of Barcelona, Barcelona, Spain; Institut de Recerca August Pi Sunyer (IDIBAPS), Barcelona, Spain; Centre for Biomedical Research on Rare Diseases (CIBER-ER), Madrid, Spain.

Classifications MeSH